Absci Corp is a biotechnology company that focuses on advancing the development of protein-based therapeutics through its innovative AI-driven platform
The company combines synthetic biology with machine learning to enhance the discovery, design, and production of complex proteins and antibodies. Absci’s technology aims to revolutionize the way biologic drugs are developed, enabling faster and more efficient creation of new drug candidates to address unmet medical needs in various therapeutic areas. By leveraging its proprietary platform, Absci aims to support pharmaceutical and biotech partners in bringing next-generation therapies to market.
VANCOUVER, Wash. and NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will report business updates and financial and operating results for the fourth quarter and full year 2024 after market close on Tuesday, March 18, 2025.
VANCOUVER, Wash. and NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced that on March 3, 2025, the company granted a non-statutory stock option to purchase an aggregate of 162,800 shares of its common stock to one newly-hired non-executive employee. The inducement grant was previously approved by the Compensation Committee of Absci’s Board of Directors pursuant to Absci’s 2023 Inducement Plan (the “Inducement Plan”), and is being made as an inducement material to the new employee’s acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).
VANCOUVER, Wash. and NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the upcoming virtual KeyBanc Capital Markets Healthcare Forum.
VANCOUVER, Wash. and NEW YORK, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the upcoming TD Cowen 45th Annual Health Care Conference in Boston, MA.
VANCOUVER, Wash. and NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the upcoming Guggenheim Securities SMID Cap Biotech Conference in New York, NY.
Collaboration combines Owkin’s novel AI target discovery and agentic AI expertise with Absci’s leading AI de novo design models to accelerate the discovery and design of potential first-in-class therapeutics
Absci shares are rising after announcing a strategic collaboration with Advanced Micro Devices Inc. The partnership will enhance Absci's AI drug discovery capabilities using AMD Instinct accelerators and ROCm software.
$20 Million Equity Investment from AMD Strengthens Absci’s Leadership in AI Drug Discovery and Further Expands Biopharma Adoption of AMD Instinct Accelerators and ROCm Software
Collaboration leverages Absci’s leading generative AI Drug Creation models to design a novel antibody Half-Life Extension (HLE) platform for animal health applications
VANCOUVER, Wash. and NEW YORK, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the upcoming 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA.
VANCOUVER, Wash. and NEW YORK, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the upcoming 36th Annual Piper Sandler Healthcare Conference in New York, NY.
